查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球輸液器市場
市場調查報告書
商品編碼
1217641

2023-2030 年全球輸液器市場

Global Infusion Sets Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

輸液器將您的胰島素泵輸送裝置連接到您的身體。 輸液器將您的胰島素泵連接到您的身體，並像靜脈輸液管一樣工作。 針通常放置在插管中，插管是放置在皮下脂肪中的小塑料管。 需要這根針刺穿皮膚才能插入該裝置。

市場動態

在整個預測期內，糖尿病患者人數的增加、市場的發展以及各機構在抗擊糖尿病方面不斷加大的努力正在推動全球輸液器市場的增長。

糖尿病患者人數的增加和市場開發的進步將在預測期內推動全球輸液器市場。

全球糖尿病患病率上升正在推動全球市場的增長。 例如，根據國際糖尿病聯合會的數據，到 2021 年，將有超過 5.37 億成年人患有糖尿病，全球每 10 人中就有 1 人患有糖尿病。 據估計，到 2030 年將增加到 6.43 億，到 2045 年將增加到 7.83 億。 四分之三的成人糖尿病患者生活在低收入和中等收入國家。 到 2021 年，糖尿病將每 5 秒奪走 1 人的生命，全球死亡人數將超過 670 萬。 2021 年全球糖尿病醫療支出約為 9660 億美元，比過去 15 年增長 316%。

超過 2.4 億糖尿病患者未確診，超過 5.41 億成年人患有 2 型糖尿病，約 2100 萬嬰兒在懷孕期間出生時患有糖尿病。我受到影響。 此外，市場開發的增加也有助於預測期內全球市場的增長。 例如，2022 年 11 月，全球醫療保健技術領導者 Medtronic plc 宣佈在美國推出首款也是唯一一款標有最長可佩戴 7 天的輸液器——Medtronic Extended 輸液器。 輸液器是將胰島素從胰島素泵輸送到體內的管子，通常需要每 2-3 天更換一次。 同樣在 2022 年 1 月，美國食品和藥物管理局 (FDA) 批准了 Capillary Biomedical (CapBio) 的研究設備豁免 (IDE)，開始對其 SteudiFlow 7 天可穿戴輸液器技術進行關鍵試驗。

產品召回阻礙了全球市場的增長。

但是，許多輸液泵產品的召回預計會阻礙預測期內的市場增長。 例如，2020 年 3 月，美國食品和藥物管理局宣布將 Becton Dickinson Alaris 系統輸液泵召回歸類為 I 類召回，這是該機構對任何可能導致嚴重傷害或死亡的醫療器械進行的最嚴格召回。這裡。

COVID-19 影響分析

預計 COVID-19 的爆發將對全球輸液器市場的增長產生積極影響。 例如，2020 年 5 月，美國食品和藥物管理局 (FDA) 為醫療保健專業人員用於治療因 COVID-19 感染引起的殘疾而使用的輸液泵和配件分配了一攬子緊急使用授權。 美國 FDA 發布了 EUA（緊急使用授權），以提高輸液泵的可用性。 因此，預計在 COVID-19 大流行期間輸液泵的使用增加將促進輸液泵和配件的生產，從而在預測期內提振輸液器市場。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 動力
      • 市場活動
      • 糖尿病患者增加
    • 約束因素
      • 產品召回
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 帶過濾器
  • 沒有過濾器

最終用戶第 8 章

  • 醫院
  • 專科診所
  • 家庭醫療機構
  • 升序

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第11章公司簡介

  • 美敦力公司。
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Tandem Diabetes
  • Micsafe Medical
  • Fresenius Kabi
  • Smith Medical
  • Becton, Dickinson and Company（BD）
  • B. Braun Melsungen AG
  • Baxter
  • Bexen Medical
  • Wuhan W.E.O Science & Technology

第12章 DataM

簡介目錄
Product Code: DMMD2824

Market Overview

The global infusion sets size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

An infusion set links the insulin pump delivery device to the body. It operates the exact way an intravenous line does. A needle is lodged inside a cannula, a tiny plastic tube normally placed under the skin in the subcutaneous fat. This needle is required to puncture the skin to insert the set.

Market Dynamics

The rising number of diabetes patients, the growing market developments and increasing initiatives by various bodies in the fight against diabetes are boosting the global infusion set market growth throughout the forecast period.

The rising cases of diabetes and growing market developents boost the global infusion set market in the forecast period.

The growing preponderance of diabetes globally is driving the global market growth. For instance, according to the International Diabetes Federation, in 2021, over 537 million adults had diabetes, making it 1 out of 10 people globally. It is estimated to rise to 643 million by 2030 and 783 million by 2045. Also, 3 in 4 adults with diabetes are in low- and middle-income countries. In 2021 diabetes caused one death every five seconds accounting for over 6.7 million deaths globally. Globally diabetes healthcare expenditure for 2021 was around $ 966 billion accounting for a 316% rise over the last 15 years.

More than 240 million cases of diabetes are undiagnosed, over 541 million adults are on the verge of developing type 2 diabetes, and around 21 million live births are affected with diabetes during pregnancy. Furthermore, the growing market developments also contribute to the global market growth during the forecast period. For instance, in November 2022, Medtronic plc, a global leader in healthcare technology, announced the U.S. launch of the Medtronic Extended infusion set, the first and only infusion set tagged for up to 7-day wear. An infusion set is tubing that transfers insulin from an insulin pump to the body and typically requires a set change every two to three days. Also, in January 2022, The U.S. Food and Drug Administration (FDA) approved the investigational device exemption (IDE) for Capillary Biomedical (CapBio) to initiate a key trial of its SteadiFlow seven-day-wear infusion set technology.

The product recalls hinders the global market growth.

However, many infusion pump product recalls are predicted to hamper the market growth during the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration announced that it had classified the Becton Dickinson Alaris System infusion pump recall as a Class I recall, the agency's most severe recall for medical devices that could cause serious injury or death.

COVID-19 Impact Analysis

The COVID-19 outbreak is anticipated to impact the global infusion set market's growth positively. For example, in May 2020, The U.S. Food and Drug Administration (FDA) allocated an umbrella emergency use approval for infusion pumps and accessories to be utilized by healthcare professionals to treat disorders caused by the COVID-19 infection. The U.S. FDA issued EUAs (Emergency Use Authorizations) that have improved the availability of infusion pumps. Therefore, the rise in infusion pump use during the COVID-19 pandemic has boosted the production of infusion pumps and accessories, which is predicted to push the infusion set market during the forecast period.

Segment Analysis

Infusion sets with filters are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

Infusion filters are employed to reliably control particles from penetrating the human body, averting life-threatening blood clots, or dispersing drugs in a specific and steady pattern. The filtration/retention rate can be determined by choosing the correct pore size. By choosing the most suitable pore size, the retention rate for undersized particles can be decided, and the flow rate for the infusion solution be selected by correlating the membrane flow rate with the priming pressure of the drug delivery solution. Also, the availability of various filters ensures the dominance of the infusion sets with filter segment dominance in the forecast period. For example, the nucleopore membrane precise filtering infusion set can effectively intercept particles and play the role of filtering particles, significantly reducing the pain caused by infusion, effectively reducing the infusion reaction, and ensuring infusion safety. Also, the track-etched membranes have a highly defined pore structure and adjustable pore size and flow parameters. They can offer a unique solution for every infusion filter application. In addition, mounting can be done conveniently with ultrasonic welding or other assembly methods. These track-etched membranes come in pore sizes of 0.1 µm up to 10.0 µm and possess irradiation stability towards Gamma and X-ray for very convenient sterilization of the whole unit. Thus, the mentioned data indicates that the infusion set with filter holds most of the global infusion set market in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

The increasing cases of diabetes in North America contribute to the dominance of this region over the global market throughout the forecast period (2022-20292); for instance, the data from the American International Diabetes Federation indicates that in 2021 in North America and the Caribbean, there were 51 million adults living with diabetes which is predicted to be 57 million by 2030 and 63 million by 2045. Also, around 1 out of 4 American adults had diabetes but were undiagnosed. In 2021 diabetes claimed over 931,000 deaths and a total of $ 415 billion expenditure for diabetes. Furthermore, the increasing government initiatives to fight against diabetes also contribute to North America's dominance over the global infusion set market throughout the forecast period. For instance, in 2021, the Government of Canada announced $35 million for investments in diabetes, specifically, $25 million for diabetes research, surveillance, and prevention, as well as the development of a national framework for diabetes.

Also, expand access to the National Diabetes Prevention Program's (National DPP) lifestyle change program, an evidence-based intervention to prevent or delay the onset of type 2 diabetes in adults at high risk. The year-long program uses a CDC-approved curriculum, is facilitated by a trained lifestyle coach, and focuses on making realistic behavior changes through healthy eating, increasing physical activity, and managing stress. Thus, owing to the data mentioned the North American infusion set market is estimated to grow at a high CAGR throughout5 the forecast period.

Competitive Landscape

The growing cases of diabetes keep the global infusion sets the market competitive. Micsafe Medical, Fresenius Kabi, Smith Medical, Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Baxter, Tandem Diabetes, Bexen Medical, and Wuhan W.E.O Science & Technology are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in July 2022, Tandem Diabetes Care acquired infusion set developer Capillary Biomedical.

Medtronic Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic plc has a MiniMed Mio Advance infusion set: This has a 90° soft cannula and can be inserted with only four steps. The all-in-one insertion design means that no separate serter is required.

The global infusion sets market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Events
      • 4.1.1.2. The Growing Cases of Diabetes
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. With Filter *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Without Filter

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. Homecare Settings
  • 8.5. ASCs

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc.
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Tandem Diabetes
  • 11.3. Micsafe Medical
  • 11.4. Fresenius Kabi
  • 11.5. Smith Medical
  • 11.6. Becton, Dickinson and Company (BD)
  • 11.7. B. Braun Melsungen AG
  • 11.8. Baxter
  • 11.9. Bexen Medical
  • 11.10. Wuhan W.E.O Science & Technology

LIST NOT EXHAUSTIVE

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us